English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/176208
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker

AutorJérémy Nigri; Gironella, Meritxell; Bressy, Christian; Vila-Navarro, Elena; Roques, Julie; Lac, Sophie; Bontemps, Caroline; Kozaczyk, Coraline; Cros, Jérôme; Pietrasz, Daniel; Maréchal, Raphaël; Van Laethem, Jean-Luc; Iovanna, Juan; Bachet, Jean-Baptiste; Folch-Puy, Emma ; Tomasini, Richard
Palabras clavePancreatic cancer
Perineural invasion
Peritumoral microenvironment
Fecha de publicaciónnov-2017
CitaciónCellular and Molecular Life Sciences 74(22): 4231–4243 (2017)
ResumenPancreatic ductal adenocarcinoma (PDA) is a fatal and insidious malignant disease for which clinicians’ tools are restricted by the current limits in knowledge of how tumor and stromal cells act during the disease. Among PDA hallmarks, neural remodeling (NR) and perineural invasion (PNI) drastically influence quality of life and patient survival. Indeed, NR and PNI are associated with neuropathic pain and metastasis, respectively, both of which impact clinicians’ decisions and therapeutic options. The aim of this study was to determine the impact and clinical relevance of the peritumoral microenvironment, through pancreatitis-associated protein (PAP/REG3A) expression, on PNI in pancreatic cancer. First, we demonstrated that, in PDA, PAP/REG3A is produced by inflamed acinar cells from the peritumoral microenvironment and then enhances the migratory and invasive abilities of cancer cells. More specifically, using perineural ex vivo assays we revealed that PAP/REG3A favors PNI through activation of the JAK/STAT signaling pathway in cancer cells. Finally, we analyzed the level of PAP/REG3A in blood from healthy donors or patients with PDA from three independent cohorts. Patients with high levels of PAP/REG3A had overall shorter survival as well as poor surgical outcomes with reduced disease-free survival. Our study provides a rationale for using the PAP/REG3A level as a biomarker to improve pancreatic cancer prognosis. It also suggests that therapeutic targeting of PAP/REG3A activity in PDA could limit tumor cell aggressiveness and PNI.
Versión del editorhttps://doi.org/10.1007/s00018-017-2579-9
Aparece en las colecciones: (IIBB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Mostrar el registro completo

Artículos relacionados:

NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.